EUVIMEDEUVIMED entdecken
Validierungsstudie

Validation of single‐cell transcriptomic profiles from Illumina and MGI Tech sequencing platforms

Valerie Vandenbempt, Michael Roach, Monika Mohenska, Kellie Wise, Taopeng Wang, Kate Harvey, Kirk Jensen, Alexander Swarbrick, Jose M Polo, Esteban N Gurzov iD, Luciano G Martelotto

FEBS Letters · 2025

DOI: 10.1002/1873-3468.70087 ↗

Kurz gefasst

Validierungsstudie in der Zeitschrift FEBS Letters, 2025. Verfasst von Valerie Vandenbempt und 10 weiteren Autor:innen. Beteiligte Einrichtung: Signal Transduction and Metabolism Laboratory, Université libre de Bruxelles, Brussels, Belgium. Hauptthemen laut MEDLINE: Single-Cell Analysis, Transcriptome, High-Throughput Nucleotide Sequencing, Gene Expression Profiling. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 27 Literaturangaben. Gefördert von: H2020 European Research Council.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

While Illumina is currently used for high‐throughput short‐read sequencing, MGI Tech have developed a similar sequencing method at a lower cost. Comparisons of the two platforms revealed that their accuracy, sensitivity, and reproducibility are very similar, but the impact of each on biological insights, particularly in heterogeneous samples, remains unknown. Illumina and MGI Tech were used to generate single‐cell RNA‐seq libraries from three human cancer samples. While unique platform‐specific cells arise after additional cell quality controls, the chosen sequencing platform did not affect either clustering or gene expression analyses. In conclusion, MGI Tech delivers transcriptomic profiles similar to those of Illumina and can be confidently used for high‐throughput applications.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Single-Cell AnalysisTranscriptomeHigh-Throughput Nucleotide SequencingGene Expression ProfilingSequence Analysis, RNAHumansReproducibility of Results

Stichwörter der Autor:innen

DNB TechnologyIlluminaMGI TechSBS technologybenchmarksingle‐cell/nucleus RNA sequencing

Autor:innen und Institutionen

  • Signal Transduction and Metabolism Laboratory, Université libre de Bruxelles, Brussels, Belgium.
  • Adelaide Centre for Epigenetics, Australia.
  • South Australian ImmunoGENomics Cancer Institute, Adelaide, Australia.
  • Faculty of Health and Medical Sciences, The University of Adelaide, Australia.
  • Single Cell and Spatial-Omics Laboratory, Adelaide Centre of Epigenetics, University of Adelaide, Australia.
  • Department of Anatomy & Developmental Biology, Biomedicine Discovery Institute, Monash University, Australia.

ORCID-Profile: Esteban N Gurzov

Förderung

  • H2020 European Research Council

Zitieren

APA

Vandenbempt, V., Roach, M., Mohenska, M., Wise, K., Wang, T., Harvey, K., Jensen, K., Swarbrick, A., Polo, J. M., Gurzov, E. N., & Martelotto, L. G. (2025). Validation of single‐cell transcriptomic profiles from Illumina and MGI Tech sequencing platforms. FEBS Letters. https://doi.org/10.1002/1873-3468.70087

Vancouver

Vandenbempt V, Roach M, Mohenska M, Wise K, Wang T, Harvey K, et al. Validation of single‐cell transcriptomic profiles from Illumina and MGI Tech sequencing platforms. FEBS Letters. 2025. doi:10.1002/1873-3468.70087

BibTeX
@article{Vandenbempt2025,
  author = {Vandenbempt, Valerie and Roach, Michael and Mohenska, Monika and Wise, Kellie and Wang, Taopeng and Harvey, Kate and Jensen, Kirk and Swarbrick, Alexander and Polo, Jose M and Gurzov, Esteban N and Martelotto, Luciano G},
  title = {Validation of single‐cell transcriptomic profiles from Illumina and MGI Tech sequencing platforms},
  journal = {FEBS Letters},
  year = {2025},
  doi = {10.1002/1873-3468.70087}
}
Kostenlos starten →